514-65-8 Usage
Uses
Used in Pharmaceutical Industry:
Bipariden is used as an anticholinergic agent for the treatment of all forms of Parkinson's disease. Its strong nicotinolytic action helps block nicotine-induced convulsions, while its weak visceral anticholinergic action minimizes side effects, making it a suitable choice for managing Parkinson's syndrome.
Used in Neurology:
Bipariden is used as a muscarinic antagonist for its effects on the central and peripheral nervous systems. Its relatively low neurotropic action on intestinal musculature and blood vessels, along with its strong musculotropic action, makes it an effective treatment option for patients with Parkinson's disease.
Used in Ophthalmology:
Although Bipariden has a mydriatic action on the eye, it is much lower than that of atropine. This property can be utilized in specific ophthalmological applications where a less potent mydriatic effect is desired.
Used in Research and Development:
Bipariden's unique combination of actions and effects make it a valuable compound for research and development in the fields of neurology, pharmacology, and drug delivery systems. Its potential applications in these areas can be further explored to develop novel therapeutic strategies and improve patient outcomes.
Therapeutic Function
Antiparkinsonian
Clinical Use
Biperiden is used in all types of Parkinson disease (postencephalitic,idiopathic, arteriosclerotic) and helps toeliminate akinesia, rigidity, and tremor. It is also usedin drug-induced extrapyramidal disorders to eliminatesymptoms and permit continued use of tranquilizers.Biperiden is also of value in spastic disorders not related toparkinsonism, such as multiple sclerosis, spinal cord injury,and cerebral palsy. It is contraindicated in all formsof epilepsy.
Safety Profile
Poison by ingestion,subcutaneous, intraperitoneal, and intravenous routes.When heated to decomposition, it emits toxic fumes ofNOx.
Synthesis
Biperiden, 1-(5-norbornen-2-yl)-1-phenyl-3-piperidinopropan-1-ol (10.2.4), is
also synthesized according to the method of making trihexyphenidyl, except by reacting
2-(1-piperidino)propiophenone (10.2.1) with 5-norbornen-2-ylmagnesiumbromide [33,34].
Check Digit Verification of cas no
The CAS Registry Mumber 514-65-8 includes 6 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 3 digits, 5,1 and 4 respectively; the second part has 2 digits, 6 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 514-65:
(5*5)+(4*1)+(3*4)+(2*6)+(1*5)=58
58 % 10 = 8
So 514-65-8 is a valid CAS Registry Number.
InChI:InChI=1/C21H29NO/c23-21(19-7-3-1-4-8-19,13-16-22-14-5-2-6-15-22)20-11-9-18(17-20)10-12-20/h1,3-4,7-9,11,18,23H,2,5-6,10,12-17H2
514-65-8Relevant academic research and scientific papers
Patch and production method thereof
-
, (2008/06/13)
The present invention relates to a patch containing a substrate, a non-crosslinked adhesive layer (A) containing a drug laminated on one surface of the substrate and a crosslinked adhesive layer (B) laminated on the adhesive layer (A). According to the present invention, the percutaneous absorbability of the drug can be improved, and a patch free of problems such as adhesive residue and adhesive bleed can be provided.
Aryl-cycloalkyl-alkanolamines for treatment of cholinergic neurotoxins
-
, (2008/06/13)
A compound and method are disclosed for reducing neurotoxic effects (such as seizures and brain damage) caused by cholinergic agents such as soman (a nerve gas) and pilocarpine (a convulsant drug used to study the mechanisms of epilepsy). Effective treatment can be provided by administering an aryl-cycloalkylalkanolamine substance having the general formula: STR1 The compoudns procyclidine, biperiden, and trihexyphenidyl fall within this class of compounds. Although not previously recognized to be effective against soman or other cholinergic neurotoxins, all three representative compounds have been discovered to be highly effective against all cholinergic neurotoxins tested to data, even when administered after actual seizures begin.
Aryl-cycloalkyl-alkanolamines for treatment of neurotoxic injury
-
, (2008/06/13)
Compounds, compositions and methods of treatment are described to control brain damage associated with anoxia or ischemia which typically follows such conditions as stroke, cardiac arrest or perinatal asphyxia. The treatment includes administration of an aryl-cycloalkyl-alkanolamine compound as an antagonist to inhibit excitotoxic actions at major neuronal excitatory amino acid receptor sites.
